PROK

ProKidney Corp.

PROK, USA

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

https://prokidney.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PROK
stock
PROK

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts MarketBeat

Read more →
PROK
stock
PROK

ProKidney (NASDAQ:PROK) Trading Down 6.8% - What's Next? MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$5.4

Analyst Picks

Strong Buy

4

Buy

0

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.30

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.63 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.68 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-14,651.15 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 45.68% of the total shares of ProKidney Corp.

1.

Suvretta Capital Management, LLC

(9.1421%)

since

2025/03/31

2.

Morgan Stanley - Brokerage Accounts

(7.6576%)

since

2025/03/31

3.

BlackRock Inc

(5.0112%)

since

2025/03/31

4.

Vanguard Group Inc

(3.8608%)

since

2025/03/31

5.

NUMC B0-B

(2.5427%)

since

2025/07/31

6.

Geode Capital Management, LLC

(1.7203%)

since

2025/03/31

7.

Bleichroeder LP

(1.4816%)

since

2025/03/31

8.

State Street Corp

(1.2788%)

since

2025/03/31

9.

MS INVF US Growth I

(1.1111%)

since

2025/03/31

10.

Brown University

(0.7408%)

since

2025/03/31

11.

GBM104 A

(0.7408%)

since

2025/07/31

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7358%)

since

2025/07/31

13.

Northern Trust Corp

(0.672%)

since

2025/03/31

14.

BrighthouseI Morgan Stanley Discovery B

(0.6292%)

since

2025/06/30

15.

Hennion & Walsh Asset Management Inc

(0.6254%)

since

2025/03/31

16.

Charles Schwab Investment Management Inc

(0.6116%)

since

2025/03/31

17.

Morgan Stanley Insight I

(0.5891%)

since

2025/06/30

18.

Morgan Stanley Insight

(0.5891%)

since

2025/06/30

19.

Bank of America Corp

(0.5577%)

since

2025/03/31

20.

GBM103 A

(0.5556%)

since

2025/07/31

21.

Morgan Stanley Inst Discovery I

(0.5432%)

since

2025/06/30

22.

Morgan Stanley Discovery

(0.5432%)

since

2025/06/30

23.

GBM102 A

(0.5185%)

since

2025/07/31

24.

MS INVF Global Insight Z

(0.4055%)

since

2025/06/30

25.

Fidelity Extended Market Index

(0.3645%)

since

2025/07/31

26.

Marshall Wace Asset Management Ltd

(0.3443%)

since

2025/06/30

27.

Schwab US Small-Cap ETFâ„¢

(0.3239%)

since

2025/08/30

28.

Morgan Stanley Inst Inception I

(0.2041%)

since

2025/06/30

29.

Morgan Stanley Inception

(0.2041%)

since

2025/06/30

30.

UBS Group AG

(0.184%)

since

2025/03/31

31.

Bank of New York Mellon Corp

(0.1775%)

since

2025/03/31

32.

Goldman Sachs Group Inc

(0.1615%)

since

2025/03/31

33.

Extended Equity Market Fund K

(0.1395%)

since

2025/06/30

34.

Fidelity Total Market Index

(0.1276%)

since

2025/07/31

35.

EQ/Morgan Stanley Small Cap Growth K

(0.1225%)

since

2025/07/31

36.

Renaissance Technologies Corp

(0.1174%)

since

2025/03/31

37.

Vanguard Total Stock Mkt Idx Inv

(0.1119%)

since

2025/07/31

38.

Susquehanna International Group, LLP

(0.1015%)

since

2025/03/31

39.

BNP Paribas Arbitrage, SA

(0.071%)

since

2025/03/31

40.

Citigroup Inc

(0.0584%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.1461

EPS Difference

0.0261

Surprise Percent

17.8645%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1)
Value
Overpriced(1)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.